Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash & Equivalents (2022 - 2025)

Atara Biotherapeutics' Cash & Equivalents history spans 4 years, with the latest figure at $8.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 66.11% year-over-year to $8.5 million; the TTM value through Dec 2025 reached $8.5 million, down 66.11%, while the annual FY2025 figure was $8.5 million, 66.11% down from the prior year.
  • Cash & Equivalents reached $8.5 million in Q4 2025 per ATRA's latest filing, up from $5.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $101.7 million in Q1 2022 to a low of $5.7 million in Q3 2025.
  • Average Cash & Equivalents over 4 years is $43.7 million, with a median of $40.5 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: decreased 0.5% in 2023, then crashed 87.64% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $92.9 million in 2022, then crashed by 72.2% to $25.8 million in 2023, then fell by 3.14% to $25.0 million in 2024, then plummeted by 66.11% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Cash & Equivalents are $8.5 million (Q4 2025), $5.7 million (Q3 2025), and $16.9 million (Q2 2025).